Sionna Therapeutics (SION) Competitors $16.92 +0.16 (+0.95%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SION vs. PTGX, IMVT, HCM, KYMR, CRNX, MOR, ALVO, GMTX, NAMS, and IBRXShould you be buying Sionna Therapeutics stock or one of its competitors? The main competitors of Sionna Therapeutics include Protagonist Therapeutics (PTGX), Immunovant (IMVT), HUTCHMED (HCM), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Gemini Therapeutics (GMTX), NewAmsterdam Pharma (NAMS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Sionna Therapeutics vs. Its Competitors Protagonist Therapeutics Immunovant HUTCHMED Kymera Therapeutics Crinetics Pharmaceuticals MorphoSys Alvotech Gemini Therapeutics NewAmsterdam Pharma ImmunityBio Sionna Therapeutics (NASDAQ:SION) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership. Do analysts prefer SION or PTGX? Sionna Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 127.54%. Protagonist Therapeutics has a consensus target price of $66.10, indicating a potential upside of 22.79%. Given Sionna Therapeutics' higher probable upside, analysts plainly believe Sionna Therapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of SION or PTGX? 98.6% of Protagonist Therapeutics shares are held by institutional investors. 3.9% of Sionna Therapeutics shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor SION or PTGX? In the previous week, Protagonist Therapeutics had 5 more articles in the media than Sionna Therapeutics. MarketBeat recorded 9 mentions for Protagonist Therapeutics and 4 mentions for Sionna Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.05 beat Sionna Therapeutics' score of 0.02 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SION or PTGX more profitable? Protagonist Therapeutics has a net margin of 27.04% compared to Sionna Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 9.22% beat Sionna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Protagonist Therapeutics 27.04%9.22%8.31% Which has preferable earnings & valuation, SION or PTGX? Protagonist Therapeutics has higher revenue and earnings than Sionna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AProtagonist Therapeutics$434.43M7.68$275.19M$0.7571.77 SummaryProtagonist Therapeutics beats Sionna Therapeutics on 11 of the 12 factors compared between the two stocks. Get Sionna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SION and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SION vs. The Competition Export to ExcelMetricSionna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$739.53M$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E RatioN/A17.6228.6723.80Price / SalesN/A269.12422.3188.12Price / CashN/A41.9535.4557.96Price / BookN/A8.508.275.55Net Income-$61.69M-$55.06M$3.24B$259.03M7 Day Performance-11.41%-3.98%-3.63%-4.56%1 Month Performance-18.93%9.59%4.40%4.49%1 Year PerformanceN/A6.72%25.97%18.05% Sionna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SIONSionna TherapeuticsN/A$16.92+1.0%$38.50+127.5%N/A$739.53MN/A0.0035Positive NewsLockup ExpirationPTGXProtagonist Therapeutics2.1166 of 5 stars$54.60+0.7%$66.10+21.1%+41.8%$3.37B$434.43M72.49120Positive NewsUpcoming EarningsIMVTImmunovant1.4287 of 5 stars$18.42+0.2%$36.30+97.1%-45.6%$3.15BN/A-6.72120Upcoming EarningsHCMHUTCHMED3.1802 of 5 stars$17.82+1.4%$23.50+31.9%-6.5%$3.11B$630.20M0.001,811Positive NewsUpcoming EarningsKYMRKymera Therapeutics3.5621 of 5 stars$46.14-0.6%$59.11+28.1%-3.4%$3.00B$47.07M-14.88170Positive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.3086 of 5 stars$30.55-1.4%$69.50+127.5%-46.5%$2.86B$1.04M-7.99210News CoverageUpcoming EarningsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech3.3682 of 5 stars$9.15-0.2%$16.00+75.0%-24.0%$2.76B$491.98M24.771,032Positive NewsGMTXGemini TherapeuticsN/A$60.94+0.3%N/A+38.5%$2.64BN/A-60.9430High Trading VolumeNAMSNewAmsterdam Pharma3.1898 of 5 stars$23.47-2.1%$41.30+76.0%+23.4%$2.63B$45.56M-12.444Upcoming EarningsIBRXImmunityBio2.2191 of 5 stars$2.98-0.5%$12.25+311.8%-50.5%$2.63B$14.74M-5.13590News CoverageGap Down Related Companies and Tools Related Companies PTGX Alternatives IMVT Alternatives HCM Alternatives KYMR Alternatives CRNX Alternatives MOR Alternatives ALVO Alternatives GMTX Alternatives NAMS Alternatives IBRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SION) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sionna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sionna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
